Immunology is entering a new era, presenting unique investment prospects as therapeutic innovations emerge and investors are eager to participate in this attractive field. Next generation I&I therapies selectively target specific disease-driving components. The innovative drugs in I&I offer the promise of unprecedented patient outcomes because they reach previously undruggable targets or selectively address immune system cell subpopulations responsible for driving the pathology of disease. Panelists will explore a range of topics, including how novel modalities enable new approaches in I&I and how companies can position and de-risk their innovative I&I drug candidates. Experts will share insights into the unique factors that drive investment decisions, clinical development plans, and business opportunities in I&I.